Parafibromin and APC as screening markers for malignant potential in atypical parathyroid adenomas.
The identification of parathyroid carcinomas is based upon histopathological criteria in which an invasive growth pattern or distant metastasis is demonstrated. A dilemma arises when tumours present with atypical histopathological features but lack direct evidence of malignancy. Recently, reduced expression or loss of the tumour suppressor proteins parafibromin and adenomatous polyposis coli (APC) has been associated with parathyroid malignancy. We report results from APC and parafibromin expression analyses by immunohistochemistry and Western blot in five cases of atypical adenoma, a single case of carcinoma and 54 adenomas without atypical features. Complete loss of APC immunoreactivity and reduced expression of parafibromin was evident in two of the atypical adenomas and in the parathyroid carcinoma. By contrast, all adenomas displayed APC expression, including two cases with hyperparathyroidism 2 gene (HRPT2) mutations and loss of parafibromin expression. We conclude that loss of APC is a frequent molecular event in atypical adenomas and carcinomas, but not in adenomas. Following verification in an independent material, APC could become a valuable tool when assessing parathyroid tumours in the clinical setting. Furthermore, the molecular resemblance of atypical adenomas with carcinoma concerning parafibromin and APC expression indicates that atypical adenomas should be subjects to watchful follow-up.
Juhlin
C Christofer
CC
Department of Molecular Medicine and Surgery, Karolinska Institutet, Karolinska University Hospital Solna, CMM L8:01, 171 76 Stockholm, Sweden. christofer.juhlin@ki.se
Nilsson
Inga-Lena
IL
Johansson
Kenth
K
Haglund
Felix
F
Villablanca
Andrea
A
Höög
Anders
A
Larsson
Catharina
C
D000236:Adenoma / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D025601:Adenomatous Polyposis Coli Protein / Q000096:biosynthesis* / Q000235:genetics; D000328:Adult; D014408:Biomarkers, Tumor / Q000032:analysis*; D015153:Blotting, Western; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D010282:Parathyroid Neoplasms / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D016133:Polymerase Chain Reaction; D025521:Tumor Suppressor Proteins / Q000096:biosynthesis* / Q000235:genetics
D025601:Adenomatous Polyposis Coli Protein; D014408:Biomarkers, Tumor; C454900:CDC73 protein, human; D025521:Tumor Suppressor Proteins
Endocr Relat Cancer. 2006 Jun;13(2):509-23
16728578
Endocr Pathol. 2008 Winter;19(4):221-5
19058032
Int J Oncol. 2009 Feb;34(2):481-92
19148484
J Clin Endocrinol Metab. 2009 Feb;94(2):434-41
19017757
Am J Clin Pathol. 1991 Nov;96(5):669-71
1719801
J Clin Endocrinol Metab. 2001 Feb;86(2):485-93
11157996
Int J Cancer. 1996 Jan 26;65(3):383-8
8575862
J Clin Endocrinol Metab. 2007 Jan;92(1):338-44
17047023
Surgery. 2008 May;143(5):630-40
18436011
Curr Opin Oncol. 2006 Jan;18(1):16-22
16357559
Br J Surg. 2007 May;94(5):566-70
17380564
Proc Natl Acad Sci U S A. 1992 May 15;89(10):4452-6
1316610
Nat Genet. 2002 Dec;32(4):676-80
12434154
Clin Cancer Res. 2004 Oct 1;10(19):6629-37
15475453
Am J Surg Pathol. 2006 Sep;30(9):1140-9
16931959
J Med Genet. 2003 Sep;40(9):657-63
12960210
Endocr Relat Cancer. 2007 Jun;14(2):501-12
17639063
J Clin Endocrinol Metab. 2004 Nov;89(11):5583-91
15531515
N Engl J Med. 2003 Oct 30;349(18):1722-9
14585940
J Clin Endocrinol Metab. 2005 Sep;90(9):5015-7
15956079
World J Surg. 1994 Jul-Aug;18(4):594-8; discussion 599
7725750
Cancer Res. 2004 Oct 15;64(20):7405-11
15492263